Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals Inc. reports news on its neuroscience-focused biopharmaceutical pipeline, including drug discovery, clinical development and commercialization plans for neurological and psychiatric disorders. The company’s lead molecule, azetukalner, is a KV7 potassium channel opener in Phase 3 clinical development for epilepsy, major depressive disorder and bipolar depression.
Recurring updates include azetukalner clinical data in focal onset seizures, presentations at medical and investor conferences, financial results, business updates, public offerings, inducement equity grants and early-stage potassium and sodium channel programs, including KV7 and NaV1.7 candidates being developed for pain.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) announced its participation at the 2023 American Academy of Neurology (AAN) Annual Meeting, showcasing its XEN1101 epilepsy program. An oral presentation by Dr. Jacqueline French will detail interim results from the open-label extension of the Phase 2b X-TOLE study, highlighting a sustained monthly seizure frequency reduction of 80%-90% from baseline and seizure freedom in 17.5% and 10.5% of patients for ≥6 and ≥12 months, respectively. Additionally, Xenon will present its Phase 3 study, X-ACKT, which evaluates XEN1101 in primary generalized tonic-clonic seizures, aiming for regulatory submissions. The trial will assess the drug's safety and efficacy in approximately 160 patients.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical firm, will present at the 2023 Bloom Burton & Co. Healthcare Investor Conference in Toronto from April 25-26, 2023. The company's presentation is scheduled for April 25, 2023, at 11:00 am Eastern Time (8:00 am Pacific Time). Investors can register for a live webcast of the event here. Ian Mortimer, the President and CEO, will be the presenter. A replay of the webcast will be available on the company's website post-event. Xenon is dedicated to developing innovative therapies for neurological disorders, particularly focusing on epilepsy.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its presentation at the 22nd Annual Needham Virtual Healthcare Conference from April 17-20, 2023. The company will participate in a fireside chat on April 20, 2023, at 2:15 PM ET (11:15 AM PT). Company executives Ian Mortimer (President and CEO) and Sherry Aulin (CFO) will present. Investors can access a live webcast of the presentation on Xenon's website, with a replay available post-event. Xenon focuses on developing innovative therapeutics for neurological disorders, particularly in epilepsy, with a commitment to addressing unmet medical needs.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a biopharmaceutical company focused on neurology, will present at the virtual Stifel 2023 CNS Days on March 28-29, 2023. The presentation will feature Ian Mortimer, President and CEO, and Sherry Aulin, CFO, on March 28 at 1:00 PM Eastern Time (10:00 AM Pacific Time). A live webcast will be available and can be pre-registered for via a provided link. Xenon is dedicated to developing innovative therapies for neurological disorders, particularly epilepsy. For further information, visit www.xenon-pharma.com.
Xenon Pharmaceuticals (NASDAQ:XENE) has advanced its XEN1101 Phase 3 epilepsy program, with ongoing trials including X-TOLE2, X-TOLE3, and X-ACKT. The company expects topline results from the XEN1101 Phase 2 X-NOVA study in major depressive disorder by Q3 2023. Financially, Xenon reported a net loss of $125.4 million for 2022, an increase from $78.9 million in 2021, due to higher R&D and G&A expenses. Cash reserves as of December 31, 2022, were $720.8 million, enough to fund operations until 2026. The company aims to address unmet needs in epilepsy and mental health disorders with its innovative therapies.